Table 2. Alterations and actionability in 171 patients with diverse cancer types.
| Patients cases | No reportable alteration (N, %) | Patients had alteration(s), but none actionable (N, %) | Approved drug(s) in the disease available (N, %)b | Approved drug(s) in another disease available (N, %)b | Experimental treatmentb (Clinical trials) available (N, %) |
|---|---|---|---|---|---|
| Histology | (On-label) | (Off-label) | |||
| Lung (N=40) | 8 (20%) | 8 (20%) | 5 (12.5%) | 24 (60%) | 24 (60%) |
| Breast (N=40) | 12 (30%) | 7 (17.5%) | 2 (5%) | 21 (52.5%) | 21 (52.5%) |
| Glioblastoma (N=33) | 24 (73%) | 3 (9%) | 0 | 6 (18%) | 6 (18%) |
| Genitourinary (N=10) | 2 (20%) | 4 (40%) | 1 (10%) | 4 (40%) | 4 (40%) |
| Gastrointestinal (N=6) | 0 | 1 (17%) | 1 (17%) | 5 (83%) | 5 (83%) |
| Othera (N=42) | 26 (62%) | 7 (16.7%) | 0 | 8 (19%) | 9 (21%) |
| OVERALL (N=171) | 72 (42%) | 30 (17.5%) | 9 (5%) | 68 (39.8%) | 69 (40%) |
a
Other included: unknown primary, n=39; melanoma, n=1; sarcoma, n=1; thymic sarcoma, n=1.
b
Note: there is some overlapping as some patients had approved agents on and off-label, as well as experimental drugs options for their disease. In total, 68 patients (39.8%) had one or more approved drug(s) as an option: 9 patients had both on- and off-label options, 59 had off-label only.